Vext Science Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue reached $14.9M, up 18% YoY, and operating cash flow doubled QoQ, but Adjusted EBITDA fell sharply as lower output and inventory costs pressured margins. Ohio growth and store expansion remain priorities as Arizona assets are repositioned.
-
Q2 saw flat sequential revenue but improved margins and profitability, driven by Ohio retail growth and the Arizona cultivation exit. Net loss narrowed 80% year-over-year, and cash flow remained strong. Focus remains on Ohio expansion, Arizona repositioning, and debt reduction.
-
Revenue rose 5% year-over-year to $12.2M, led by Ohio's 34% growth, while Arizona declined 24% amid wholesale compression. Gross profit more than doubled, adjusted EBITDA margin improved to 29%, and net loss narrowed to $0.9M. Ohio retail expansion and Arizona streamlining remain key priorities.
Fiscal Year 2025
-
Revenue grew 43% year-over-year to $51.4M, with operating cash flow up 256% to $11.7M, driven by Ohio retail expansion. Arizona operations shifted to a retail-first model, exiting cultivation to optimize margins. DEA reclassification could materially reduce tax liabilities.
-
Q3 2025 saw 41% year-over-year revenue growth to $12.7M, driven by Ohio retail expansion and resilient Arizona operations. Margins were pressured by Arizona price declines, but positive cash flow and improved cultivation yields position the company for a strong Q4 and continued growth into 2026.
-
Q2 2025 saw 59% revenue growth and a 30% adjusted EBITDA margin, driven by rapid Ohio retail expansion and disciplined Arizona operations. Free cash flow and operating leverage improved, with a focus on scaling Ohio and maintaining profitability in a challenging Arizona market.
-
Q1 2025 saw revenue rise 38% year-over-year to $11.6M, with strong cash flow and a 29% Adjusted EBITDA margin. Ohio retail growth and disciplined cost management drove results, while Arizona outperformed its market despite headwinds.
Fiscal Year 2024
-
2024 saw strong revenue and EBITDA growth, driven by Ohio's adult use market launch, while Arizona faced pricing pressure but outperformed the market. Cash flow from operations hit a three-year high, with expansion in Ohio and debt reduction prioritized for 2025โ2026.
-
Q3 2024 saw 11% revenue growth to $9M and Adjusted EBITDA of $2.9M, driven by Ohio's adult-use launch and resilient Arizona performance. Ohio dispensaries posted over 200% sequential growth, while Arizona outperformed state averages despite market headwinds.
-
Q2 2024 revenue was $8.4M, with adjusted EBITDA of $1.1M and a 12.9% margin. Ohio adult-use sales launched post-quarter, driving strong initial demand, while Arizona faced margin pressure but outperformed state averages. Cash flow is expected to improve as Ohio scales.